T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (368)	1/7/1999 6:12:00 PM
From: EZLibra	of 1073

Hi Rick. A lot of learned people have doubts about the practicality of inducing localized thrombosis in humans. Don't they have the same doubts about Folkmanlike projects? From acorns grow... Thanks for the history on Phil Thorpe and deglycosolated ricin a chain. As I remember he was trying to poison the vessel but the potential for liver toxicity was too great. About a year ago he was causing the thrombosis with IgM abs but of course they were too large and the 1% production yield was causing problems. Now he's using IgG abs (96% yield) and results are promising. He expects to determine the ab for the clinic this year. Still it's a big and expensive project so we shareholders expect TCLN to license it off to Big Pharma. TNT is still our holy grail. Thanks for listening. Regards, -Davis

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next